- 1 Pathway-based Rare Variant Burden Analysis Identifies a Role for the Complement System in an
- 2 Extreme Phenotype of Sepsis with Coagulopathy
- 3 Pavan K. Bendapudi<sup>1,2,3</sup>, Sumaiya Nazeen<sup>3,4</sup>, Justine Ryu<sup>1,3</sup>, Onuralp Söylemez<sup>3,4</sup>, Betty Rouaisnel<sup>5</sup>,
- 4 Meaghan Colling<sup>2,3</sup>, Bryce Pasko<sup>6</sup>, Alissa Robbins<sup>7</sup>, Michael Bouzinier<sup>3,4</sup>, Lindsay Tomczak<sup>1</sup>, Lindsay
- 5 Collier<sup>1</sup>, Sanjay Ram<sup>8</sup>, Agnes Toth-Petroczy<sup>3,4</sup>, Joel Krier<sup>3,4</sup>, Elizabeth Fieg<sup>4</sup>, Walter H. Dzik<sup>2,3</sup>, James
- 6 C. Hudspeth<sup>9,10</sup>, Olga Pozdnyakova<sup>3,11</sup>, Valentina Nardi<sup>3,12</sup>, Richard Maas<sup>3,4</sup>, Shamil Sunyaev<sup>3,4</sup>, Julie-
- 7 Aurore Losman<sup>3,5,13\*</sup>
- <sup>1</sup>Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Boston, MA; <sup>2</sup>Division
- 9 of Hematology and Blood Transfusion Service, Massachusetts General Hospital, Boston, MA; <sup>3</sup>Harvard
- 10 Medical School, Boston, MA; <sup>4</sup>Division of Genomic Medicine, Brigham and Women's Hospital, Boston,
- 11 MA; <sup>5</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; <sup>6</sup>Department of
- Pathology, University of Colorado School of Medicine; <sup>7</sup>Immunology Division, Walter and Eliza Hall
- 13 Institute of Medical Research, Melbourne, Australia; <sup>8</sup>Division of Infectious Diseases and Immunology,
- 14 University of Massachusetts Medical School, Worcester, MA; <sup>9</sup>Department of Medicine, Boston
- Medical Center, Boston, MA; <sup>10</sup>Boston University School of Medicine, Boston, MA; <sup>11</sup>Department of
- Pathology, Brigham and Women's Hospital, Boston, MA; <sup>12</sup>Department of Pathology, Massachusetts
- 17 General Hospital, Boston, MA; <sup>13</sup>Division of Hematology, Brigham and Women's Hospital, Boston,
- 18 MA
- \*Email of corresponding author: julieaurore\_losman@dfci.harvard.edu

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

Extreme disease phenotypes have the potential to provide key pathophysiologic insights, but the study of these conditions is challenging due to their rarity and the limited statistical power of existing methods. Herein, we apply a novel pathway-based approach to investigate the role of rare genomic variants in infectious purpura fulminans (PF)<sup>1,2</sup>, an extreme phenotype of sepsis with hyperinflammation and coagulopathy for which the role of inherited risk factors is currently unknown. Using whole exome sequencing, we found a significantly increased burden of rare, putatively function-altering coding variants in the complement system in patients with PF compared to unselected patients with sepsis (p-value = 0.01). Functional characterization of a subset of PF-associated variants in integrin complement receptors 3 and 4 (CR3 and CR4) revealed that they exhibit a pro-inflammatory phenotype. Our results suggest that rare inherited defects in the complement system predispose individuals to the maladaptive hyperinflammatory response that characterizes severe sepsis. Rare coding variants are instrumental in identifying genes and pathways involved in disease biology. However, analyses of rare variants using traditional single-variant and single-gene association tests often fail even with large sample sizes<sup>3</sup>, and the assembly of patient cohorts with uncommon diseases presents an additional challenge. Two strategies can overcome these barriers: (i) conducting extreme phenotype studies (EPS) to amplify the effects of rare variants<sup>21-24</sup>, and (ii) leveraging prior biological knowledge by applying collapsing tests at the level of pathways in which multiple genes function together with directionally consistent effects<sup>4-6</sup>. In sepsis, dysregulation of the host response to infection causes harmful levels of systemic inflammation, leading to end-organ damage<sup>7</sup>. The clinical acuity of sepsis varies dramatically, and it is currently impossible to predict which patients will experience a severe disease course. Attempts to identify genetic factors underlying the risk for sepsis have been limited to small genome wide association studies (GWAS)<sup>8-11</sup> and a single whole exome sequencing study of 74 patients<sup>12</sup>. However, due to the

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

heterogeneity of the patient population, the lack of a narrowly defined clinical phenotype, the diversity of pathogens involved in sepsis, and the inherent limitations of GWAS, these efforts have been largely inconclusive. A well-designed EPS focusing on pathways that could plausibly contribute to disease pathophysiology has the potential to overcome these challenges and elucidate novel biology that is generalizable to the broader population of septic patients. To identify genetic risk factors for severe sepsis, we undertook a case-controlled EPS of the complement system in infectious PF, an exceptionally rare and devastating extreme sepsis phenotype<sup>1</sup>. The defining feature of PF is uncontrolled systemic inflammation and thrombotic coagulopathy resulting in microvascular thrombosis, end-organ damage, and death. Mortality is as high as 80%, and survivors typically experience extensive scarring and dismemberment<sup>1,2,13</sup>. The complement system (Figure 1A), which is responsible for the initial inflammatory response to infection, has long been considered a key driver of inflammation in severe sepsis and PF<sup>14-17</sup>. Microbes directly activate the humoral complement cascade, a tightly-regulated series of proteolytic reactions that result in pathogen destruction by the membrane attack complex (MAC) and release of highly inflammatory microbial cell components. Activated complement proteins also function as potent inflammatory mediators (anaphylatoxins) that promote shock and other features of sepsis. During this process, the complement fragment C3b is deposited on microbial surfaces, where it is converted to iC3b, a potent opsonin that binds integrin complement receptors CR3 and CR4 on macrophages 18,19. This leads to phagocytosis of microbes and activation of immunomodulatory signaling. Integrins are each composed of an  $\alpha$  and a  $\beta$  subunit, different combinations of which give rise to receptors with distinct physiologic roles. CR3 ( $\alpha_M\beta_2$ ) is composed of integrin  $\beta_2$  (ITGB2) paired with integrin  $\alpha_M$  (ITGAM), whereas CR4 ( $\alpha_X\beta_2$ ) is composed of integrin β<sub>2</sub> paired with integrin α<sub>X</sub> (ITGAX). Intracellular signaling via CR3 promotes an antiinflammatory and immunoregulatory cytokine profile, whereas CR4 signaling promotes a proinflammatory state (Figure 1B)<sup>20-22</sup>. Given that inflammation stemming from infection is strongly

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

associated with aberrant activation of coagulation<sup>23-25</sup>, we reasoned that rare function-altering mutations in the complement system could plausibly contribute to the pathophysiology of PF. To assemble a sequencing cohort of patients with this rare, highly lethal condition, we combined prospective sample collection with a unique automated "look back" approach in which we leveraged natural language processing to perform enterprise-scale deep mining of the electronic medical record system to identify historical cases of PF. Using this technique, we were able to locate archived pathology specimens suitable for germline sequencing from PF patients who were deceased or lost to follow up. In total, we identified 40 clinically well-annotated PF patient samples and, as controls, utilized 87 unselected patients with sepsis from the NHLBI ARDSnet iSPAAR consortium (Supplementary Tables 1 and 2). Whole exome sequencing data from all 127 samples were jointly called using the GATK pipeline v3.5. After performing variant-level and sample-level quality control (QC), we removed three PF patient samples (Supplementary Figure 1). In the remaining specimens, we analyzed qualifying variants in the complement system with a gnomAD global minor allele frequency (MAF) of < 0.05 as well as those with an optimal in-cohort frequency cutoff selected using a variable thresholds (VT) approach<sup>26</sup>. Missense variants predicted to be "deleterious" or "possibly deleterious" by either PolyPhen2 or SIFT were grouped with high-precision loss of function (LoF) variants (stop gained, stop lost, splice donor, splice acceptor, splice region variant, and frameshift and in-frame indel) and together were termed "ΔP variants." Interrogating the effects of rare variants in a pathway using an EPS design requires addressing two issues. Firstly, population structure can inflate the false positive rate in both the common and rare variant space<sup>27</sup>. This issue can be mitigated by analyzing EPS cohorts of a single ancestry. Secondly, existing pathway-based collapsing approaches frequently focus only on the presence or absence of rare variants and are of limited value because many individuals will have at least one rare variant in a large pathway.

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

This challenge necessitates a new test that focuses on the number of qualifying rare variants rather than simply their presence or absence. To assess population structure, we performed principal component analysis (PCA) on the study samples (Supplementary Figure 2). We found that all 87 sepsis controls but only 24/37 PF patients were of European descent, and we therefore limited our primary analysis to individuals of European ancestry. To rule out the possibility that other unrecognized population structures could introduce bias into our analysis, we evaluated the distribution of ultra-rare (i.e., doubletons and tripletons) missense and synonymous variants shared between the 24 European PF cases and 87 controls and observed no significant differences (Supplementary Table 3). Across the entire Boston PF Cohort (N=37), we identified a total of 58 unique missense variants in the complement system (N = 27 autosomal genes) (Supplementary Table 4) with MAF < 0.05, of which 42 were present only in the PF cohort and 16 were present in both the PF and control cohorts (Table 1 and Supplementary Tables 5 and 6). Of these, 32 (55.2%) were annotated as functionally significant in silico. We also found 26 high-precision LoF variants. Of these, 22 were specific to PF patients and 4 were found in both PF and control patients. In total, 58 unique  $\Delta P$  variants were identified in PF patients. In the control cohort of unselected patients with sepsis (N=87), we identified a total of 68 unique rare missense variants, of which 52 were present only among the controls and 16 were present in both cohorts. Of these, 39/68 (57.3%) were putatively function altering. The control cohort also contained 15 highprecision LoF variants, for a total of 54 ΔP variants. Of note, inclusion of non-European PF patients increased the burden of rare  $\Delta P$  variants when compared to the European-only PF patient cohort (Supplementary Figure 3), which suggests that PF patients have an increased proportion of rare  $\Delta P$ variants in the complement system regardless of ethnic background. However, we cannot validate this conclusion without a control cohort having the same population structure.

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

To determine whether  $\Delta P$  variants are enriched in PF patients, we devised a novel rare variant trend test (RVTT) utilizing the Cochran-Armitage statistic to assess the relationship between complement system variant burden and disease status<sup>28,29</sup>. We performed RVTT on the European PF patients (N=24) and sepsis controls (N=87) using a fixed gnomAD MAF cutoff of 0.05 as well as a variable thresholds approach with or without an in-cohort MAF cutoff. We observed a significant linear trend in the number of complement system  $\Delta P$  variants in the PF patients compared to controls (gnomAD cutoff: permutation p-value = 0.0168, z-score = 2.5; VT approach with MAF cutoff up to 0.05: permutation p-value = 0.0134, z-score = 2.62; VT approach without cutoff: p-value = 0.0278, z-score = 2.72) (Table 2, Figure 1C). To determine whether the association of  $\Delta P$  variants with PF was independent of clinical and demographic parameters, we generated a multivariate logistic regression model incorporating age, sex, and Sequential Organ Failure Assessment (SOFA) score, a validated composite measure of illness severity in critical care patients that encompasses 8 distinct clinical criteria<sup>30</sup>. After adjusting for these co-variates, we found that the number of  $\Delta P$  variants per subject independently predicted PF in the patients of European ancestry (OR=2.61 per ΔP variant, 95% CI: 1.29-6.1, P=0.01) (Table 3). Including all patients in the analysis yielded a similar result. This finding suggests that multiple  $\Delta P$  variants in a single patient contribute to the development of PF and orthogonally confirms the association found using RVTT. Notably, a simple one-sided collapse and combine (CMC) Fisher's exact test of  $\Delta P$  variants in the complement system at a gnomAD global MAF cutoff of 0.05 was borderline significant (p-value: 0.0418) (Supplementary Table 7), and when we performed gene-based collapsing analyses using the CMC-Fisher<sup>31</sup>, VT-Price<sup>26</sup>, KBAC<sup>32</sup>, and SKAT<sup>33</sup> tests, none of the genes in the complement system individually showed a significant enrichment of rare  $\Delta P$  variants in PF cases after Bonferroni correction (Supplementary Table 8). This result further supports our approach of performing a pathway-based collapsing analysis that leverages prior biological knowledge. Finally, to rule out the possibility that the

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

observed  $\Delta P$  RVTT signal resulted from a technical artifact, we repeated RVTT with synonymous and predicted functionally neutral missense variants in the complement pathway and observed no significant linear trend (Table 2, Figure 1C). To further ensure the validity of our findings, we also performed RVTT on two additional gene sets: (i) the coagulation system, a distinct pathway that could plausibly be implicated in PF, and (ii) glycolysis, an unrelated pathway (Supplementary Table 4). Neither gene set demonstrated an enrichment in  $\Delta P$  variants in the PF cohort (Table 2, Figure 1D). Of the 58 unique  $\Delta P$  variants identified in PF patients, 15 (25.9%) were found in genes encoding subunits of CR3 and CR4. Given the dearth of functional data on these variants and their high frequency in PF patients, we cloned all 11 ITGB2, ITGAM, and ITGAX variants found in the Boston PF cohort (Supplementary Figure 4) and characterized the resultant CR3 and CR4 receptors. We found that intracellular expression levels of all the cloned variants were similar (Supplementary Figure 5). However, cell-surface expression of the CR3 variants was significantly lower than that of wild-type CR3 (Figure 2A), whereas cell-surface expression of the CR4 variants was similar to that of wild-type CR4 (Figure 2B). Notably, the D283N mutation in the shared  $\beta_2$  subunit resulted in complete loss of CR3 surface expression without affecting the surface level of CR4. We also assessed binding of the variants to iC3b. Of the CR3 variants, 6/8 (75%) demonstrated significantly reduced binding to iC3b compared to wild-type CR3 (Figure 2C). By contrast, 4/7 (57.1%) CR4 variants showed similar iC3b binding to wild-type and, unexpectedly, 3/7 (42.9%) demonstrated increased binding compared to wild-type CR4 (Figure 2D). Given that the mutant CR4 lines all expressed equivalent or slightly reduced surface levels compared to wild-type, the observed increase in iC3b binding to specific CR4 mutants likely reflects an increased affinity of those mutants for iC3b. Finally, we used a dual-luciferase reporter assay to assess the impact of the PF-associated CR3 and CR4 variants on TNFα-mediated activation of the canonical pro-inflammatory transcription factor NF-κB. Relative to untransfected control cells, NF-κB activation was suppressed by expression of wild-type CR3 and was enhanced by expression of wild-type CR4

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

(Figure 3A). The 7 expressed CR3 variants were associated with increased activation of NF-κB compared to wild-type CR3. 6/7 (85.7%) CR4 variants showed increased NF-κB activation compared to wild-type CR4. Taken together, these findings suggest that PF-associated CR3/4 variants result in a relative loss of anti-inflammatory CR3 function and a relative gain of pro-inflammatory CR4 function. In summary, we applied RVTT, a new pathway-based mutational burden analysis approach, to an EPS of sepsis and demonstrated a relationship between rare, putatively function-altering complement system variants and the development of infectious PF. Functional characterization of PF-associated complement receptor variants identified mutations that result in loss of anti-inflammatory signaling (Figure 3B) or gain of pro-inflammatory signaling (Figure 3C), consistent with the phenotype of severe sepsis with coagulopathy<sup>34</sup>. We also identified several examples of single mutations in the shared complement receptor subunit integrin β<sub>2</sub> that simultaneously enhance pro-inflammatory signaling and abrogate antiinflammatory signaling (Figure 3D), a novel finding in complement receptor biology. Our genetic and functional studies support a model in which PF is driven by a genetically-encoded maladaptive inflammatory response to infection, findings that will help to risk-stratify patients with sepsis and inform the development of novel strategies to treat the thrombo-inflammatory complications of severe infection. This study also serves as a model for leveraging known biological pathways to gain insights into the genetics of extreme phenotypes and rare conditions. Several questions remain that warrant further investigation. Firstly, due to the limited availability of clinical cases, we were unable to analyze the roles of specific microbes in the pathogenesis of PF. Secondly, our approach cannot rule out that other, as yet unidentified, genetic modifiers influence the predisposition to PF. Despite these limitations, this study represents an important step forward in defining the genetic determinants of severe sepsis.

Table 1: Complement system variants found in the study cohorts. The number and types of complement system variants identified in the Boston PF cohort (PF) (N = 37) and the NHLBI ARDSnet iSPAAR Unselected Sepsis (US) cohort (N = 87).

	Total PF- associated variants	Total US associated- variants	PF-specific variants	US-specific variants	Shared variants
Neutral	26	29	16	19	10
Missense	58	68	42	52	16
Missense <sup>F</sup>	32	39	26	33	6
HP LoF	26	15	22	11	4
ΔP variants	58	54	48	44	10

- 187 Missense<sup>F</sup> = missense variants predicted *in silico* to cause altered protein function
- 188 HP LoF = high-precision loss-of-function
- 189  $\Delta P \text{ variants} = \text{Missense}^F + \text{HP LoF}$

185

Table 2. Rare variant burden assessed by Rare Variant Trend Test (RVTT) in quality-filtered European PF cases (N=24) and sepsis controls (N=87). We applied RVTT on three gene sets: the complement system, the coagulation system, and the glycolysis pathway. For each gene set, we tested rare  $\Delta P$ , synonymous, and neutral missense variants. Qualifying rare variants were selected using three settings: (i) fixed threshold: gnomAD MAF < 0.05, (ii) variable threshold with no cutoff, and (iii) variable threshold with a cutoff of MAF = 0.05. We observed a significant enrichment of rare  $\Delta P$  variants in the complement system under all three settings.

Туре	RVTT- Fixed Test Statistic (gnomAD cutoff)	RVTT- Fixed Perm p-value (gnomAD cutoff)	RVTT- Variable Selected Threshold (No Cutoff)	RVTT- Variable Test Statistic (No Cutoff)	RVTT- Variable Perm p-value (No Cutoff)	RVTT- Variable Selected Threshold (cutoff = 0.05)	RVTT- Variable Test Statistic (cutoff = 0.05)	RVTT- Variable Perm p-value (cutoff = 0.05)
	Complement System Pathway							
$\Delta P$ variants	2.4951	0.0168	0.0833	2.7229	0.0278	0.0463	2.6236	0.0134
Synonymous	1.5071	0.1368	0.25	1.1308	0.8166	0.0463	1.0267	0.4438
Neutral missense	1.0195	0.323	0.3704	1.0636	0.8954	0.0463	0.7881	0.7237
Coagulation Pathway								
$\Delta P$ variants	1.3329	0.1866	0.015	0.9856	0.5718	0.0114	0.9856	0.6519
Synonymous	1.68	0.0996	0.205	1.4318	0.3251	0.0114	1.2291	0.4873
Neutral missense	0.7912	0.4864	0.068	1.3924	0.4095	0.0265	0.8997	0.7392
Glycolysis Pathway								
ΔP variants	0.0536	0.9563	0.035	1.0827	0.5804	0.0315	1.0827	0.5265
Synonymous	0.1035	0.9256	0.185	1.4843	0.309	0.0079	0.8554	0.7307
Neutral missense	0.3942	0.7607	0.169	1.8254	0.2089	0.0118	0.6315	0.7491

## Table 3: Multivariate logistic regression model of predictors of purpura fulminans.

EUR Only Analysis (N=111)						
	β	SE	OR (95% CI)	P value		
ΔP variants	0.96	0.39	2.61 (1.29-6.1)*	0.01		
Sex	-1.58	0.93	0.21 (0.03-1.18)	0.09		
Age	-0.05	0.02	0.95 (0.91-0.99)†	0.02		
SOFA Score <sup>††</sup>	0.67	0.16	1.96 (1.49-2.87) †††	< 0.0001		
Entire Study Analysis (N=124)						
	β	SE	OR (95% CI)	P value		
ΔP variants	1.05	0.33	2.85 (1.58-5.90)*	0.002		
Sex	-1.02	0.81	0.36 (0.07-1.72)	0.21		
Age	-0.06	0.02	0.94 (0.90-0.98)†	0.005		
SOFA Score <sup>††</sup>	0.75	0.17	2.12 (1.59-3.16) †††	< 0.0001		

198 \* Per  $\Delta P$  variant

197

†Per year of age


201

202

<sup>††</sup>Composite measure comprised of: PaO<sub>2</sub>, FiO<sub>2</sub>, mechanical ventilation status, platelet count, Glasgow

Coma Scale, total bilirubin level, mean arterial pressure, and creatinine level.

††† Per one point increase in SOFA score



**Figure 1: Mutational Analysis of Purpura Fulminans.** (A) Schematic of the complement system. The complement system is broadly divided into two sub-pathways: humoral and opsonophagocytic. The humoral sub-pathway is comprised of soluble plasma proteins responsible for destroying microorganisms via formation of the membrane attack complex (MAC), which permeabilizes the surface

of the target cell. The opsonophagocytic sub-pathway is comprised of cellular receptors that recognize complement fragments deposited on microbial surfaces and facilitate phagocytosis and pathogen clearance. (**B**) Heterodimerization of integrin  $\beta_2$  (B2) with integrin  $\alpha_M$  (M) forms the anti-inflammatory signaling mediator complement receptor 3 (CR3) whereas heterodimerization of B2 with integrin  $\alpha_X$  (X) forms the pro-inflammatory signaling mediator complement receptor 4 (CR4). (**C**) RVTT analyses comparing the European PF Cohort (PF) and the NHLBI ARDSnet iSPAAR cohort (Unselected Sepsis) in terms of  $\Delta P$  variants (left panel), neutral missense variants (middle panel), and synonymous various (right panel). (**D**) RVTT analyses comparing the two cohorts in terms of  $\Delta P$  variants in the coagulation system (left panel) and glycolysis pathway (right panel).




Figure 2: Expression and ligand binding of the CR3 and CR4 variants. (A-B) Wild-type (WT) and mutant complement receptors were cloned and expressed in HEK-293T cells, and surface expression levels of CR3 (A) and CR4 (B) were evaluated by flow cytometry for integrin  $\beta_2$  (ITGB2/CD18). WT CR3 and CR4 are depicted in black. Receptors containing a mutant integrin  $\beta_2$  subunit are depicted in blue, those with a mutant integrin  $\alpha_M$  (ITGAM) subunit are depicted in red, and those with a mutant integrin  $\alpha_X$  (ITGAX) subunit are depicted in green. (C-D) The ability of receptor-expressing cells to bind immobilized iC3b was assessed in a solid-phase functional assay. iC3b binding activity of WT and mutant CR3 (C) and WT and mutant CR4 (D) are shown. ITGB2 P7Q, ITGAM R663W, ITGAM H687R, ITGAM T1001N, and ITGAX V1019M were predicted *in silico* to be benign. \*P<0.05 compared to WT/WT control.




Figure 3: Signaling by the CR3 and CR4 variants. (A) TNFα-mediated activation of an NF-κB dual luciferase reporter in cells expressing the PF-associated CR3 variants (left panel) or CR4 variants (right panel) in the presence or absence of the CR3/CR4 ligand iC3b. Control HEK-293T cells not expressing CR3 or CR4 (untransfected) and HEK-293T cells expressing wild-type or mutant CR3 or CR4 were used as negative and positive controls, respectively. Data are shown as the mean fluorescence intensity ratio of the iC3b-plus condition to the iC3b-minus condition. Error bars represent standard error of the mean.

(B) PF-associated mutations in *ITGAM* (M\*) reduce the ability of mutant CR3 (CR3\*) to suppress inflammatory signaling. (C) PF-associated mutations in *ITGAX* (X\*) enhance the ability of mutant CR4 (CR4\*) to activate inflammatory signaling. (D) PF-associated mutations in the shared subunit *ITGB2* 

- 235 (B2\*) simultaneously decrease suppression of inflammatory signaling by CR3\* and increase activation
- of inflammatory signaling by CR4\*.

## References

- 238 1. Colling ME, Bendapudi PK. Purpura Fulminans: Mechanism and Management of Dysregulated Hemostasis. Transfusion medicine reviews 2018;32(2):69-76. (In eng).
- 240 2. Lerolle N, Carlotti A, Melican K, et al. Assessment of the interplay between blood and skin vascular 241 abnormalities in adult purpura fulminans. American journal of respiratory and critical care medicine 242 2013;188(6):684-92. (In eng). DOI: 10.1164/rccm.201302-0228OC.
- 243 3. Povysil G, Petrovski S, Hostyk J, Aggarwal V, Allen AS, Goldstein DB. Rare-variant collapsing analyses for complex traits: guidelines and applications. Nature reviews Genetics 2019;20(12):747-759. (In eng). DOI: 10.1038/s41576-019-0177-4.
- Lee S, Choi S, Kim YJ, Kim BJ, Hwang H, Park T. Pathway-based approach using hierarchical components of collapsed rare variants. Bioinformatics 2016;32(17):i586-i594. (In eng). DOI: 10.1093/bioinformatics/btw425.
- 249 5. Richardson TG, Timpson NJ, Campbell C, Gaunt TR. A pathway-centric approach to rare variant 250 association analysis. European journal of human genetics: EJHG 2016;25(1):123-129. (In eng). DOI: 251 10.1038/ejhg.2016.113.
- Kousi M, Söylemez O, Ozanturk A, et al. Evidence for secondary-variant genetic burden and nonrandom distribution across biological modules in a recessive ciliopathy. Nature genetics 2020;52(11):1145-1150. (In eng). DOI: 10.1038/s41588-020-0707-1.
- Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers 2016;2:16037.
   (In eng). DOI: 10.1038/nrdp.2016.37.
- 257 8. D'Urso S, Rajbhandari D, Peach E, et al. Septic Shock: A Genomewide Association Study and Polygenic 258 Risk Score Analysis. Twin research and human genetics: the official journal of the International Society 259 for Twin Studies 2020;23(4):204-213. (In eng). DOI: 10.1017/thg.2020.60.
- 260 9. Rautanen A, Mills TC, Gordon AC, et al. Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. The Lancet Respiratory medicine 2015;3(1):53-60. (In eng). DOI: 10.1016/s2213-2600(14)70290-5.
- Scherag A, Schöneweck F, Kesselmeier M, et al. Genetic Factors of the Disease Course after Sepsis: A
   Genome-Wide Study for 28Day Mortality. EBioMedicine 2016;12:239-246. (In eng). DOI:
   10.1016/j.ebiom.2016.08.043.
- 266 11. Srinivasan L, Page G, Kirpalani H, et al. Genome-wide association study of sepsis in extremely 267 premature infants. Archives of disease in childhood Fetal and neonatal edition 2017;102(5):F439-f445. 268 (In eng). DOI: 10.1136/archdischild-2016-311545.
- Taudien S, Lausser L, Giamarellos-Bourboulis EJ, et al. Genetic Factors of the Disease Course After
   Sepsis: Rare Deleterious Variants Are Predictive. EBioMedicine 2016;12:227-238. (In eng). DOI:
   10.1016/j.ebiom.2016.08.037.
- 272 13. Bendapudi PK, Robbins A, LeBoeuf N, et al. Persistence of endothelial thrombomodulin in a patient 273 with infectious purpura fulminans treated with protein C concentrate. Blood advances 274 2018;2(21):2917-2921. (In eng). DOI: 10.1182/bloodadvances.2018024430.
- Landsem A, Fure H, Krey Ludviksen J, et al. Complement component 5 does not interfere with
   physiological hemostasis but is essential for Escherichia coli-induced coagulation accompanied by Toll-like receptor 4. Clinical and experimental immunology 2019;196(1):97-110. (In eng). DOI:
   10.1111/cei.13240.
- Lappegard KT, Christiansen D, Pharo A, et al. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc Natl Acad Sci U S A 2009;106(37):15861-6. (In eng). DOI: 10.1073/pnas.0903613106.
- 282 16. Janco RL, Morris P. Serum augments the generation of monocyte procoagulant stimulated by bacterial lipopolysaccharide or chemotactic fragments of C5. Thrombosis research 1983;32(1):73-86. (In eng). DOI: 10.1016/0049-3848(83)90156-1.

- Lupu F, Keshari RS, Lambris JD, Coggeshall KM. Crosstalk between the coagulation and complement
   systems in sepsis. Thrombosis research 2014;133 Suppl 1(0 1):S28-31. (In eng). DOI:
   10.1016/j.thromres.2014.03.014.
- Dustin ML. Complement Receptors in Myeloid Cell Adhesion and Phagocytosis. Microbiology spectrum 2016;4(6) (In eng). DOI: 10.1128/microbiolspec.MCHD-0034-2016.
- 290 19. Abram CL, Lowell CA. The ins and outs of leukocyte integrin signaling. Annual review of immunology 2009;27:339-62. (In eng). DOI: 10.1146/annurev.immunol.021908.132554.
- Jawhara S, Pluskota E, Cao W, Plow EF, Soloviev DA. Distinct Effects of Integrins alphaXbeta2 and alphaMbeta2 on Leukocyte Subpopulations during Inflammation and Antimicrobial Responses.
   Infection and immunity 2017;85(1):e00644-16. (In eng). DOI: 10.1128/iai.00644-16.
- 21. Dai S, Rajaram MV, Curry HM, Leander R, Schlesinger LS. Fine tuning inflammation at the front door: macrophage complement receptor 3-mediates phagocytosis and immune suppression for Francisella tularensis. PLoS pathogens 2013;9(1):e1003114. (In eng). DOI: 10.1371/journal.ppat.1003114.
- 298 22. Rosetti F, Mayadas TN. The many faces of Mac-1 in autoimmune disease. Immunological reviews 299 2016;269(1):175-93. (In eng). DOI: 10.1111/imr.12373.
- 300 23. Dellinger RP. Inflammation and coagulation: implications for the septic patient. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2003;36(10):1259-65. (In eng). DOI: 10.1086/374835.
- Levi M, van der Poll T. Coagulation and sepsis. Thrombosis research 2017;149:38-44. (In eng). DOI: 10.1016/j.thromres.2016.11.007.
- Levi M, Keller TT, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system.

  Cardiovasc Res 2003;60(1):26-39. (In eng). DOI: 10.1016/s0008-6363(02)00857-x.
- Price AL, Kryukov GV, de Bakker PI, et al. Pooled association tests for rare variants in exonresequencing studies. Am J Hum Genet 2010;86(6):832-8. (In eng). DOI: 10.1016/j.ajhg.2010.04.005.
- Panarella M, Burkett KM. A Cautionary Note on the Effects of Population Stratification Under an
   Extreme Phenotype Sampling Design. Frontiers in genetics 2019;10:398. (In eng). DOI:
   10.3389/fgene.2019.00398.
- 312 28. Cochran WG. Some Methods for Strengthening the Common χ2 Tests. Biometrics 1954;10(4):417-451.
- 313 29. Armitage P. Tests for Linear Trends in Proportions and Frequencies. Biometrics 1955;11(3):375-386. 314 DOI: 10.2307/3001775.
- 31. Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Critical care medicine 1998;26(11):1793-800. (In eng). DOI: 10.1097/00003246-199811000-00016.
- 31. Li B, Leal SM. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am J Hum Genet 2008;83(3):311-21. (In eng). DOI: 10.1016/j.ajhg.2008.06.024.
- 32. Liu DJ, Leal SM. A novel adaptive method for the analysis of next-generation sequencing data to detect complex trait associations with rare variants due to gene main effects and interactions. PLoS genetics 2010;6(10):e1001156. (In eng). DOI: 10.1371/journal.pgen.1001156.
- 32. Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet 2011;89(1):82-93. (In eng). DOI: 10.1016/j.ajhg.2011.05.029.
- 328 34. Girardin E, Grau GE, Dayer JM, Roux-Lombard P, Lambert PH. Tumor necrosis factor and interleukin-1 329 in the serum of children with severe infectious purpura. The New England journal of medicine 330 1988;319(7):397-400. (In eng). DOI: 10.1056/nejm198808183190703.